TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by US Bancorp DE

US Bancorp DE lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 20.5% during the 4th quarter, Holdings Channel reports. The firm owned 3,818 shares of the biopharmaceutical company’s stock after selling 986 shares during the period. US Bancorp DE’s holdings in TG Therapeutics were worth $115,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the business. Proficio Capital Partners LLC acquired a new stake in shares of TG Therapeutics during the fourth quarter worth about $306,000. Illinois Municipal Retirement Fund acquired a new stake in shares of TG Therapeutics during the fourth quarter worth about $2,351,000. Bank of New York Mellon Corp lifted its position in shares of TG Therapeutics by 10.5% during the fourth quarter. Bank of New York Mellon Corp now owns 923,488 shares of the biopharmaceutical company’s stock worth $27,797,000 after purchasing an additional 87,679 shares in the last quarter. IFP Advisors Inc lifted its position in shares of TG Therapeutics by 44.5% during the fourth quarter. IFP Advisors Inc now owns 178,547 shares of the biopharmaceutical company’s stock worth $5,374,000 after purchasing an additional 54,983 shares in the last quarter. Finally, World Equity Group Inc. acquired a new stake in shares of TG Therapeutics during the fourth quarter worth about $211,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock opened at $40.84 on Monday. The firm has a market capitalization of $6.41 billion, a P/E ratio of -408.36 and a beta of 2.30. TG Therapeutics, Inc. has a 52 week low of $12.93 and a 52 week high of $41.85. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The firm’s 50 day moving average is $31.86 and its two-hundred day moving average is $29.08.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. Research analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on TGTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday, November 25th. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $30.29, for a total value of $343,397.73. Following the transaction, the chief financial officer now directly owns 670,632 shares in the company, valued at $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.